Pyranoindazoles and their use for the treatment of glaucoma

A compound represented by Formula I:

• 14
• wherein R1 and R2 are independently chosen from hydrogen or an alkyl group;
• R3 and R4 are independently hydrogen or an alkyl group or;
• R3 and R4 and the carbon atom to which they are attached form a cycloalkyl ring, or;
• R2 and R3 together form a saturated (CH2)m heterocycle;
• R5 is hydrogen, halogen, or a substituted or unsubstituted alkyl group;
• R6 and R7 are independently hydrogen, halogen, cyano, an alkylthio, or a substituted or unsubstituted alkyl group;
• R8 and R9 are independently hydrogen, hydroxyl, a substituted or unsubstituted alkyl group, an alkoxy, ═O, NR10R11, OC(═O)NR1R2, OC(═O)C1-4alkyl, or an alkylthiol;
• R10 and R11 are independently hydrogen, a substituted or unsubstituted alkyl group, C(═O)C1-4 alkyl, C(═O)OC1-4 alkyl, or C(═O)NR1R2 or R10 and R11 together complete a saturated 5 or 6-membered heterocyclic ring, which optionally includes an additional heteroatom selected from N, O, or S when a 6-membered ring;
• A is (CH2)n, C═O, or CHC1-4alkyl;
• B is either a single or a double bond, wherein when B is a double bond, R8 and R9 are selected from hydrogen, or a substituted or unsubstituted alkyl group;
• m=2-4;
• n=0-2;
• X and Y are either N or C, wherein X and Y are different;
• and the dashed bonds denote a suitably appointed single and double bond.